Endosense is a medical technology company based in Meyrin (GE) focused on catheter ablation treatments of cardiac rhythm disorders, including atrial fibrillation (AF). The company has developed and pioneered the use of contact force measurement in catheter ablation, with the development of the proprietary Touch+® sensor technology and TactiCath®, Endosense’s flagship product. AF is the most common form of cardiac arrhythmia. Endosense is focused on providing those patients with a safe, effective and minimally invasive treatment option. TactiCath® is the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. TactiCath received CE Mark approval in April 2009 and FDA PMA approval in 2014.
Endosense was sold to St. Jude Medical in 2013 for total cash consideration of up to CHF 309m (USD 331m).